Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Cécile Borel"'
Autor:
Camille Gondran, Pierre-Yves Dumas, Emilie Bérard, Audrey Bidet, Eric Delabesse, Suzanne Tavitian, Thibaut Leguay, Françoise Huguet, Cécile Borel, Edouard Forcade, François Vergez, Jean-Philippe Vial, Jean Baptiste Rieu, Nicolas Lechevalier, Isabelle Luquet, Alban Canali, Emilie Klein, Audrey Sarry, Anne-Charlotte de Grande, Arnaud Pigneux, Christian Récher, Laetitia Largeaud, Sarah Bertoli
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Acute myeloid leukemia (AML) with t(9;22) (q34.1; q11.2)/BCR::ABL1, a distinct entity within the group of AML with defining genetic abnormalities, belong to the adverse-risk group of the 2022 ELN classification. However, there is little data
Externí odkaz:
https://doaj.org/article/4053055ddfc042fab15037068bcb7414
Autor:
Guillaume Beziat, Suzanne Tavitian, Francois-Xavier Arnaud, Françoise Izar, Justine Attal, Cécile Borel, Christian Recher, Anne Ducassou
Publikováno v:
Journal of Contemporary Brachytherapy, Vol 14, Iss 6, Pp 601-604 (2022)
Acute myeloid leukemia (AML) may extend to extra-medullary sites at diagnosis or at relapse, either isolated or associated with bone marrow disease. Granulocytic sarcoma of uterine cervix is rare, and there is no established treatment for this diseas
Externí odkaz:
https://doaj.org/article/a5330ccd3e294c3ebc6ab5deac3846b9
Autor:
Olivier Tournilhac, Magali Le Garff-Tavernier, Stéphanie Nguyen Quoc, Edouard Forcade, Patrice Chevallier, Faezeh Legrand-Izadifar, Gandhi Laurent Damaj, David Michonneau, Cécile Tomowiak, Cécile Borel, Corentin Orvain, Pascal Turlure, Rabah Redjou, Gaëlle Guillerm, Laure Vincent, Celestine Simand, Richard Lemal, Claire Quiney, Patricia Combes, Bruno Pereira, Laure Calvet, Aurélie Cabrespine, Jacques-Olivier Bay, Véronique Leblond, Nathalie Dhédin, French Innovative Leukemia Organization (FILO), Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Publikováno v:
Haematologica, Vol 106, Iss 7 (2020)
Allogeneic hematopoietic stem cell transplantation (HSCT) remains a potentially curative and useful strategy in high-risk relapsing CLL. Minimal Residual Disease (MRD) assessment at 12 months post-HSCT is predictive of relapse. This phase 2 study aim
Externí odkaz:
https://doaj.org/article/513b282ddfd94a8f8cbad1c4cbd28f6d
Autor:
Aurore Perrot, Hélène Monjanel, Réda Bouabdallah, Philippe Quittet, Clémentine Sarkozy, Marc Bernard, Aspasia Stamatoullas, Cécile Borel, Krimo Bouabdallah, Emmanuelle Nicolas-Virelizier, Marion Fournier, Franck Morschhauser, Pauline Brice
Publikováno v:
Haematologica, Vol 101, Iss 4 (2016)
Brentuximab vedotin was reported to be effective and safe against refractory/relapsed Hodgkin lymphoma in cohorts of between 12 to 102 patients. Herein we report our retrospective analysis of the French experience with brentuximab vedotin used alone
Externí odkaz:
https://doaj.org/article/20f61625144a461e9bfb2fd5049b5b39
Autor:
Karen Delavigne, Emilie Bérard, Sarah Bertoli, Jill Corre, Eliane Duchayne, Cécile Demur, Véronique Mansat-De Mas, Cécile Borel, Muriel Picard, Muriel Alvarez, Audrey Sarry, Françoise Huguet, Christian Récher
Publikováno v:
Haematologica, Vol 99, Iss 3 (2014)
Hemophagocytic lymphohistiocytosis is a condition of immune dysregulation characterized by severe organ damage induced by a hyperinflammatory response and uncontrolled T-cell and macrophage activation. Secondary hemophagocytic lymphohistiocytosis typ
Externí odkaz:
https://doaj.org/article/98a32f47c3f343629294f0358be80ef8
Autor:
Eric Van Den Neste, Olivier Casasnovas, Marc André, Mohamed Touati, Delphine Senecal, Véronique Edeline, Aspasia Stamatoullas, Luc Fornecker, Bénédicte Deau, Thomas Gastinne, Oumédaly Reman, Isabelle Gaillard, Cécile Borel, Pauline Brice, Christophe Fermé
Publikováno v:
Haematologica, Vol 98, Iss 8 (2013)
The Hodgkin’s Lymphoma Committee of the Lymphoma Study Association (LYSA) gathered in 2012 to prepare guidelines on the management of transplant-eligible patients with relapsing or refractory Hodgkin’s lymphoma. The working group is made up of a
Externí odkaz:
https://doaj.org/article/e040960e05534e6c9bd9eeaf36a0dc45
Autor:
Emmanuelle Bouvet, Cécile Borel, Lucie Obéric, Gisèle Compaci, Bruno Cazin, Anne-Sophie Michallet, Guy Laurent, Loic Ysebaert
Publikováno v:
Haematologica, Vol 98, Iss 1 (2013)
Fludarabine-cyclophosphamide-rituximab is the most efficient first-line treatment for chronic lymphocytic leukemia patients. Many dose adjustments of the original MD Anderson Cancer Center regimen have been proposed. However, whether fludarabine-cycl
Externí odkaz:
https://doaj.org/article/ad0d28aedfa84810bbd9df577c8c66f3
Autor:
Imran Ahmad, Laetitia Souchet, Fati Hamzy, Patrice Ceballos, Yohann Desbrosses, Aurélie Ravinet, Pascal Turlure, Alban Villate, Cécile Borel, Hanane Benbarkat, Ibrahim Yakoub-Agha, Thierry Guillaume
Publikováno v:
Bulletin du Cancer. 110:S56-S66
Autor:
Valérie Coiteux, Laurène Fenwarth, Nicolas Duployez, Malika Ainaoui, Cécile Borel, Alice Polomeni, Ibrahim Yakoub-Agha, Yves Chalandon
Publikováno v:
Bulletin du Cancer. 110:S13-S29
Autor:
Aspasia Stamatoullas, Hervé Ghesquières, Pierre Feugier, Marc André, Fabien Le Bras, Anne-Claire Gac, Cécile Borel, Thomas Gastinne, Philippe Quittet, Franck Morschhauser, Vincent Ribrag, Stephanie Guidez, Emmanuelle Nicolas-Virelizier, Alina Berriolo-Riedinger, Thierry Vander Borght, Véronique Edeline, Pauline Brice
Publikováno v:
Leukemia & lymphoma, Vol. 63, no. 13, p. 3063-3071 (2022)
Leukemia & lymphoma
Leukemia & lymphoma, 2022, Leukemia & lymphoma, 63 (13), pp.3063-3071. ⟨10.1080/10428194.2022.2107204⟩
Leukemia & lymphoma
Leukemia & lymphoma, 2022, Leukemia & lymphoma, 63 (13), pp.3063-3071. ⟨10.1080/10428194.2022.2107204⟩
This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients. Phase I study was designed to dete